3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0.05
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-0.37%-3.67%+57.21%+87.75% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
-0.66%+0.66%+33.84%+16.10% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-7.59% 20.74B
-1.70%+0.43%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
+4.53%-3.02%-4.08%+520.63% 14.23B
Average +0.34%-0.11%+37.38%+171.28% 30.57B
Weighted average by Cap. +0.09%-1.08%+37.96%+129.26%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock